Obermatt
See Similar Stocks →

Flags

Financial distress

Harvard Bioscience

NAQ:HBIO · US4169061052
Life Sciences Tools & ServicesSmall

360

21
EV / EBIT92
Price / Owner Earnings57
Owner Earnings Yield1
Dividend Yield1
Price/Sales100
EV / Gross Profit93
Price/Book31
Return on Capital64
Cash Return on Capital48
Return on Equity8
EBIT Margin57
Gross Profitability96
Accruals63
Owner Earnings Margin55
Sales growth30
Profit growth33
Reinvestment82
Price momentum69
Debt load6
Refinancing99
Debt Payback1
Liquidity51
Analyst ratings11
Opinion Changes50
Price Target Upside4
Market mood9
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Harvard Bioscience doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2000
Employees169
Websiteharvardbioscience.com
ISINUS4169061052
Last UpdateApr 2, 2026
Index & Theme
CardiovascularHealth DiagnosticsSensorsRespiratoryBiomedical EngineeringDetectors, Sensors and MemsNeuroscienceCentral Nervous SystemBiotechnologyLife ScienceManufacturing

Description

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction, and preclinical te…

Analysis

Middle-of-the-road

Harvard Bioscience, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is fragile. The company scores 4/20 on our value-creation score: not creating value. Analyst sentiment is cautious.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
30
2023202420252026

All-time high

61

Jan 2024

All-time low

18

Mar 2026

Average rank

41

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
100
94
75
93
Price/Earnings
84
93
84
96
Price/Book
31
86
47
64
Dividend Yield
1
1
1
1
Value (overall)
73
95
74
97

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Harvard Bioscience with its peers
Alpha Teknova
NMQ:TKNO
32
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Bruker
NSQ:BRKR
41
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
MaxCyte
NSQ:MXCT
17
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Illumina
NSQ:ILMN
77
CountryUSA
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →
Bio-Techne
NSQ:TECH
74
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
MindWalk Holdings
NAQ:HYFT
59
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →